Injection technology company PharmaJet revealed on Tuesday that its Needle-free Injection System (NFIS) will be used in a clinical trial that will deliver a booster vaccine against COVID-19 virus variants.
The vaccine is reportedly developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK,
Under the University of Cambridge's Phase 1 clinical trial, the COVID-19 vaccine will be delivered exclusively with the PharmaJet Tropis Needle-free injection system, which was selected based on its ability to increase the efficacy of nucleic acid-based vaccines and therapeutics.
This is the 20th COVID-19 vaccine development programme using PharmaJet Needle-free Injection Systems as their method of delivery.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA